These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7734295)

  • 1. Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
    Hietanen P; Blomqvist C; Wasenius VM; Niskanen E; Franssila K; Nordling S
    Br J Cancer; 1995 May; 71(5):1029-32. PubMed ID: 7734295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
    Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
    Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.
    Stanton PD; Cooke TG; Oakes SJ; Winstanley J; Holt S; George WD; Murray GD
    Br J Cancer; 1992 Nov; 66(5):925-9. PubMed ID: 1419638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason grade, S-phase fraction and DNA ploidy.
    Vesalainen S; Nordling S; Lipponen P; Talja M; Syrjänen K
    Br J Cancer; 1994 Aug; 70(2):309-14. PubMed ID: 8054280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
    Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
    J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose epirubicin + cyclophosphamide (HD-EC) in metastatic breast cancer: a dose-finding study.
    Nagel GA; Beyer JH; Holtkamp W; Emrich D; Kneba M; Luig H; Marschner N; Rauschning W; Unger C; Wander HE
    Onkologie; 1988 Dec; 11(6):287-8. PubMed ID: 3071764
    [No Abstract]   [Full Text] [Related]  

  • 8. Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.
    Brooks SA; Leathem AJ; Camplejohn RS; Gregory W
    Breast Cancer Res Treat; 1993; 25(3):247-56. PubMed ID: 8369526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Bonnefoi H; Potti A; Delorenzi M; Mauriac L; Campone M; Tubiana-Hulin M; Petit T; Rouanet P; Jassem J; Blot E; Becette V; Farmer P; André S; Acharya CR; Mukherjee S; Cameron D; Bergh J; Nevins JR; Iggo RD
    Lancet Oncol; 2007 Dec; 8(12):1071-1078. PubMed ID: 18024211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
    Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
    Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of the S-phase fraction of breast cancers treated by primary radiotherapy or neoadjuvant chemotherapy.
    Remvikos Y; Mosseri V; Zajdela A; Fourquet A; Durand JC; Pouillart P; Magdelénat H
    Ann N Y Acad Sci; 1993 Nov; 698():193-203. PubMed ID: 8279757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
    Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
    J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer.
    Lopez M; Papaldo P; Di Lauro L; Vici P; Carpano S; Conti EM
    Oncology; 1989; 46(1):1-5. PubMed ID: 2915887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AgNORs in ductal breast cancer: correlation with ploidy and S-phase fraction by DNA flow cytometry.
    Borgiani L; Cogorno P; Oliviero J; Toso F; Gambini G; Tunesi G; Canepa M
    Eur J Histochem; 1994; 38(2):171-6. PubMed ID: 7524814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA flow cytometry and response to preoperative chemotherapy for primary breast cancer.
    O'Reilly SM; Camplejohn RS; Rubens RD; Richards MA
    Eur J Cancer; 1992; 28(2-3):681-3. PubMed ID: 1591092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.